Want to see GB:AGY full AI Analyst Report?
AGY Stock Chart & Stats
11.80 p
-0.04 p(-0.55%)
At close: 4:00 PM EST
11.80 p
-0.04 p(-0.55%)
Day’s Range― - ―
52-Week Range6.50 p - 12.10 p
Previous CloseN/A
Volume22.64K
Average Volume (3M)460.33K
Market Cap
£443.28M
Enterprise Value394.82M
Total Cash (Recent Filing)£10.08M
Total Debt (Recent Filing)£26.75M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Sep 24, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding6,332,530,000
10 Day Avg. Volume433,490
30 Day Avg. Volume460,334
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)-13.44
Price to Sales (P/S)6.88
P/FCF Ratio-11.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£63.00M
Bulls Say, Bears Say
Bulls Say
Disease-modifying Business ModelAllergy Therapeutics' focus on immunotherapy that modifies the immune response represents a durable business model: disease‑modifying treatments can command differentiated clinical value, create higher patient/provider stickiness, and support longer-term treatment protocols versus symptomatic therapies.
R&D Pipeline For Next-gen TreatmentsA stated pipeline targeting next‑generation allergy treatments supports medium-term structural upside: successful pipeline progress can extend product life cycles, enable label expansion or new indications, and shift revenue mix toward higher‑margin proprietary offerings if clinical/regulatory milestones are met.
Operational Scale (headcount)A workforce of 612 indicates material operational capacity to run R&D, manufacturing relationships, and commercial activities. That scale supports sustained product development and market execution, lowering execution risk relative to very small entrants and enabling continued regulatory and commercialization efforts.
Bears Say
Declining Revenue And Weak MarginsAn 11% revenue decline and a deeply negative net margin (‑72.9%) signal structural demand or pricing challenges and poor profitability. Persistently shrinking top line and weak margins erode reinvestment capacity, constrain scale economics, and make sustainable operating leverage difficult to achieve over months.
Negative Cash GenerationMaterial negative operating and free cash flows, with free cash flow contracting by 172.7%, indicate the business is burning cash to fund operations and growth. This reduces runway, raises reliance on external financing, and limits the company's ability to fund R&D or commercialization without dilutive or costly capital.
Stressed Balance SheetNegative shareholders' equity and a debt-to-equity ratio of -2.13 point to financial instability and constrained borrowing capacity. A stressed balance sheet limits strategic flexibility, increases refinancing and covenant risk, and can necessitate equity issuance or asset sales to sustain operations over the medium term.
Allergy Therapeutics News
AGY FAQ
What was Allergy Therapeutics PLC’s price range in the past 12 months?
Allergy Therapeutics PLC lowest share price was 6.50 p and its highest was 12.10 p in the past 12 months.
What is Allergy Therapeutics PLC’s market cap?
Allergy Therapeutics PLC’s market cap is £443.28M.
When is Allergy Therapeutics PLC’s upcoming earnings report date?
Allergy Therapeutics PLC’s upcoming earnings report date is Sep 24, 2026 which is in 87 days.
How were Allergy Therapeutics PLC’s earnings last quarter?
Allergy Therapeutics PLC released its earnings results on Mar 31, 2026. The company reported -0.004 p earnings per share for the quarter, the consensus estimate of -0.004 p by 0 p.
Is Allergy Therapeutics PLC overvalued?
According to Wall Street analysts Allergy Therapeutics PLC’s price is currently Overvalued.
Does Allergy Therapeutics PLC pay dividends?
Allergy Therapeutics PLC does not currently pay dividends.
What is Allergy Therapeutics PLC’s EPS estimate?
Allergy Therapeutics PLC’s EPS estimate is >-0.01.
How many shares outstanding does Allergy Therapeutics PLC have?
Allergy Therapeutics PLC has 6,332,530,000 shares outstanding.
What happened to Allergy Therapeutics PLC’s price movement after its last earnings report?
Allergy Therapeutics PLC reported an EPS of -0.004 p in its last earnings report, expectations of -0.004 p. Following the earnings report the stock price went down -1.905%.
Which hedge fund is a major shareholder of Allergy Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:AGY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Allergy Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.35%
12-Months-Change
Fundamentals
Return on Equity
409.00%
Trailing 12-Months
Asset Growth
-2.69%
Trailing 12-Months
Company Description
Allergy Therapeutics PLC
Allergy Therapeutics plc is a biotechnology firm dedicated to the research and development of innovative treatments for allergies. The company offers a range of injectable and sublingual immunotherapies specifically targeting allergens, alongside diagnostic tools and prescription solutions for pollen-related allergies, including those caused by grasses, weeds, and trees. Its diverse product portfolio features Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. Furthermore, Allergy Therapeutics is actively advancing new vaccine candidates designed to address sensitivities to trees, grass, house dust mites, animal dander, and peanuts. With operations spanning Central Europe, Southern Europe, the United Kingdom, and various other international markets, Allergy Therapeutics plc was established in 2004 and is headquartered in Worthing, UK.
Technical Analysis
Animalcare
―
Hikma Pharmaceuticals
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Options Prices
Currently, No data available
---